Multiple Myeloma Clinical Trial
A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders
This is an observational study that will include both participants with relapsed/refractory Multiple Myeloma and their doctors. The purpose of this study is to gather information about the use of hematopoietic cell transplantation/HCT and B-cell maturation antigen /BCMS targeted chimeric antigen receptor/CAR autologous T-cell therapy.
Diagnosis of Multiple Myeloma after January 1, 2017.
Karnofsky Performance Status > 70%
≥ 2 lines of prior therapy
Started new line of therapy for RRMM within the last 12 months prior to registration
Age 18-80 years of age.
English or Spanish speaking.
Willing to provide informed consent
Willing to perform study procedures.
Be a Co-Investigator
Agree to comply with study procedures
Active CNS disease
Patients who have already been referred will not be included.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 7 Locations for this study
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.